Exercise may shield shift workers from body clock chaos
NCT ID NCT07668622
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether exercise can help protect the body from health problems caused by shift work, which disrupts natural sleep-wake cycles. Sixteen healthy but inactive adults will spend 5 days in a lab, simulating day shifts then night shifts, with some doing exercise. Researchers will measure blood pressure and blood sugar responses to see if exercise makes a difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- exercise
- What this could lead to
- If successful, this could point toward simple exercise routines to help shift workers maintain better heart and metabolic health.
- What could go wrong
- This is a very small, early proof-of-concept study with only 16 participants, so results may not apply broadly. It also uses simulated shift work, not real-world conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRCADIAN MISALIGNMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test